English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduPatients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center
Tag: Soft Tissue Sarcoma
Tumor microbiome linked to immunotherapy success in sarcoma patients
A new UC Davis study reveals the interaction between tumor microbiome and the immune system may be the secret to improving outcomes for sarcoma patients.
Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center.
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
ASTRO issues clinical guideline on radiation therapy for soft tissue sarcoma in adults
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on radiation therapy for soft tissue sarcoma. Recommendations outline optimal radiation dosing, techniques and treatment planning, with a focus on preserving long-term functionality through individualized care.